Emilia Sippert , Evgeniya Volkova , Meagan Rippee-Brooks , Gregory A. Denomme , Willy A. Flegel , Christine Lee , Richardae Araojo , Orieji Illoh , Zhugong Liu , Maria Rios
{"title":"用于 RH 变异基因分型的 DNA 参考试剂。","authors":"Emilia Sippert , Evgeniya Volkova , Meagan Rippee-Brooks , Gregory A. Denomme , Willy A. Flegel , Christine Lee , Richardae Araojo , Orieji Illoh , Zhugong Liu , Maria Rios","doi":"10.1016/j.jmoldx.2024.02.005","DOIUrl":null,"url":null,"abstract":"<div><p>Patients who carry Rhesus (RH) blood group variants may develop Rh alloantibodies requiring matched red blood cell transfusions. Serologic reagents for Rh variants often fail to specifically identify variant Rh antigens and are in limited supply. Therefore, red blood cell genotyping assays are essential for managing transfusions in patients with clinically relevant Rh variants. Well-characterized DNA reference reagents are needed to ensure quality and accuracy of the molecular tests. Eight lyophilized DNA reference reagents, representing 21 polymorphisms in <em>RHD</em> and <em>RHCE,</em> were produced from an existing repository of immortalized B-lymphoblastoid cell lines at the Center for Biologics Evaluation and Research/US Food and Drug Administration. The material was validated through an international collaborative study involving 17 laboratories that evaluated each DNA candidate using molecular assays to characterize <em>RHD</em> and <em>RHCE</em> alleles, including commercial platforms and laboratory-developed testing, such as Sanger sequencing, next-generation sequencing, and third-generation sequencing. The genotyping results showed 99.4% agreement with the expected results for the target <em>RH</em> polymorphisms and 87.9% for <em>RH</em> allele agreement. Most of the discordant <em>RH</em> alleles results were explained by a limited polymorphism coverage in some genotyping methods. Results of stability and accelerated degradation studies support the suitability of these reagents for use as reference standards. The collaborative study results demonstrate the qualification of these eight DNA reagents for use as reference standards for <em>RH</em> blood group genotyping assay development and analytical validation.</p></div>","PeriodicalId":50128,"journal":{"name":"Journal of Molecular Diagnostics","volume":"26 6","pages":"Pages 456-466"},"PeriodicalIF":3.4000,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"DNA Reference Reagents for Genotyping RH Variants\",\"authors\":\"Emilia Sippert , Evgeniya Volkova , Meagan Rippee-Brooks , Gregory A. Denomme , Willy A. Flegel , Christine Lee , Richardae Araojo , Orieji Illoh , Zhugong Liu , Maria Rios\",\"doi\":\"10.1016/j.jmoldx.2024.02.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Patients who carry Rhesus (RH) blood group variants may develop Rh alloantibodies requiring matched red blood cell transfusions. Serologic reagents for Rh variants often fail to specifically identify variant Rh antigens and are in limited supply. Therefore, red blood cell genotyping assays are essential for managing transfusions in patients with clinically relevant Rh variants. Well-characterized DNA reference reagents are needed to ensure quality and accuracy of the molecular tests. Eight lyophilized DNA reference reagents, representing 21 polymorphisms in <em>RHD</em> and <em>RHCE,</em> were produced from an existing repository of immortalized B-lymphoblastoid cell lines at the Center for Biologics Evaluation and Research/US Food and Drug Administration. The material was validated through an international collaborative study involving 17 laboratories that evaluated each DNA candidate using molecular assays to characterize <em>RHD</em> and <em>RHCE</em> alleles, including commercial platforms and laboratory-developed testing, such as Sanger sequencing, next-generation sequencing, and third-generation sequencing. The genotyping results showed 99.4% agreement with the expected results for the target <em>RH</em> polymorphisms and 87.9% for <em>RH</em> allele agreement. Most of the discordant <em>RH</em> alleles results were explained by a limited polymorphism coverage in some genotyping methods. Results of stability and accelerated degradation studies support the suitability of these reagents for use as reference standards. The collaborative study results demonstrate the qualification of these eight DNA reagents for use as reference standards for <em>RH</em> blood group genotyping assay development and analytical validation.</p></div>\",\"PeriodicalId\":50128,\"journal\":{\"name\":\"Journal of Molecular Diagnostics\",\"volume\":\"26 6\",\"pages\":\"Pages 456-466\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-03-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Molecular Diagnostics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1525157824000540\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Molecular Diagnostics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525157824000540","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
携带 RH 血型变异体的患者可能会出现 Rh 同种抗体,需要输注匹配的红细胞。Rh 变异血清学试剂往往不能特异性地识别变异的 Rh 抗原,而且供应有限。因此,红细胞基因分型检测对于管理临床相关 Rh 变异患者的输血至关重要。为确保分子检测的质量和准确性,需要特性良好的 DNA 参考试剂。CBER/U.S. FDA 从现有的永生化 B 淋巴细胞系库中提取了 8 种冻干 DNA 参考试剂,代表了 RHD 和 RHCE 的 21 种多态性。该材料通过一项国际合作研究进行了验证,17 个实验室参与了这项研究,使用分子检测方法对每个候选 DNA 进行了评估,以确定 RHD 和 RHCE 等位基因的特征,包括商业平台和实验室开发的检测方法,如桑格测序、新一代测序和第三代测序。基因分型结果显示,目标 RH 多态性与预期结果的一致性为 99.4%,RH 等位基因的一致性为 87.9%。大多数不一致的 RH 等位基因结果是由于某些基因分型方法的多态性覆盖范围有限造成的。稳定性和加速降解研究结果表明,这些试剂适合用作参考标准。合作研究结果表明,这八种 DNA 试剂可用作 RH 血型基因分型检测开发和分析验证的参考标准。
Patients who carry Rhesus (RH) blood group variants may develop Rh alloantibodies requiring matched red blood cell transfusions. Serologic reagents for Rh variants often fail to specifically identify variant Rh antigens and are in limited supply. Therefore, red blood cell genotyping assays are essential for managing transfusions in patients with clinically relevant Rh variants. Well-characterized DNA reference reagents are needed to ensure quality and accuracy of the molecular tests. Eight lyophilized DNA reference reagents, representing 21 polymorphisms in RHD and RHCE, were produced from an existing repository of immortalized B-lymphoblastoid cell lines at the Center for Biologics Evaluation and Research/US Food and Drug Administration. The material was validated through an international collaborative study involving 17 laboratories that evaluated each DNA candidate using molecular assays to characterize RHD and RHCE alleles, including commercial platforms and laboratory-developed testing, such as Sanger sequencing, next-generation sequencing, and third-generation sequencing. The genotyping results showed 99.4% agreement with the expected results for the target RH polymorphisms and 87.9% for RH allele agreement. Most of the discordant RH alleles results were explained by a limited polymorphism coverage in some genotyping methods. Results of stability and accelerated degradation studies support the suitability of these reagents for use as reference standards. The collaborative study results demonstrate the qualification of these eight DNA reagents for use as reference standards for RH blood group genotyping assay development and analytical validation.
期刊介绍:
The Journal of Molecular Diagnostics, the official publication of the Association for Molecular Pathology (AMP), co-owned by the American Society for Investigative Pathology (ASIP), seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome for review articles that contain: novel discoveries or clinicopathologic correlations including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, clinical informatics, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods which may be applied to diagnosis or monitoring of disease or disease predisposition.